Pharmaceuticals News and Research

RSS

Report: FDA conflict-of-interest rules too restrictive

The conflict-of-interest policies in the medical profession are coming under fire as too stringent and as impeding medical progress, a claim the Food and Drug Administration dismisses as a misunderstanding of its rules.

8 Nov 2010

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

Sanofi Pasteur's dengue vaccine enters phase III trial in Australia

Sanofi Pasteur, the vaccines division of the pharmaceutical group Sanofi-Aventis, on Thursday announced the company had begun testing its dengue fever vaccine in a Phase III clinical trial in Australia, Dow Jones/Wall Street Journal reports.

8 Nov 2010

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Jasco Pharmaceuticals, LLC was awarded a grant under the US Government's Patient Protection and Affordable Care Act (PPACA) of 2010. The grant was related to Jasco Pharma's novel small molecule Pim inhibitor program intended to develop therapeutics for the treatment of cancer.

8 Nov 2010

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

8 Nov 2010

Research Roundup: Basing insurance on results, not cost; Americans skeptical of public health efforts; seniors' comprehensive care

Copayment Reductions Generate Greater Medication Adherence In Targeted Patients. As health care costs have increased, some patients have sought to save money by cutting down on their medications.

8 Nov 2010

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

APP Drug Hotline to assist healthcare professionals with shortage issues

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it will launch the APP Drug Hotline on Wednesday, November 10, 2010. The APP Drug Hotline has been established to assist healthcare professionals with critical drug shortage issues.

7 Nov 2010

Al Jazeera examines international trade agreement negotiations, access to generic medicines in low-income countries

Al Jazeera examines what the outcomes of two international trade agreement negotiations - one regarding free trade between the EU and India and the other over anti-counterfeiting measures - could mean for patients living with HIV/AIDS in low-income countries.

7 Nov 2010

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Arena Pharmaceuticals, Inc. announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010.

7 Nov 2010

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Pisgah Labs, Inc., an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant.

4 Nov 2010

Watson third quarter net revenue increases 33% to $882.4 million

Watson Pharmaceuticals, Inc. today reported net revenue grew 33 percent for the third quarter ended September 30, 2010 to $882.4 million, compared to $662.1 million in the third quarter 2009. On an adjusted cash basis, net income increased 18 percent to $105.9 million or $0.85 per share, compared to $90.0 million or $0.78 per share in the third quarter 2009.

4 Nov 2010

Omeros third quarter net loss increases to $7.6 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced its financial results for the third quarter of 2010.

4 Nov 2010

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

4 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

First Edition: November 4, 2010

Less than 24 hours after Republicans won control of the House, soon-to-be-speaker John Boehner denounced the new health care law, saying it would "kill jobs in America, ruin the best health care system in the world, and bankrupt our country" -- and renewed his vow to try to repeal it. Kaiser Health News asked people around the country to answer the following question: "If you ended up in an elevator with Rep. Boehner, what single thing would you urge him to do about health care in this country? (Kaiser Health News).

4 Nov 2010

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported third quarter 2010 results today.

4 Nov 2010

CaPre drug candidate effective in managing impaired glucose tolerance

Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. reports preclinical results showing that its leading drug candidate CaPre, performed significantly better than the currently marketed drug, Lovaza, at managing impaired glucose tolerance (IGT) a serious pre-diabetic state associated with increased risk of diabetes and heart disease.

4 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

Valeant declares one-time special dividend

Valeant Pharmaceuticals International, Inc. today announced that the Company's Board of Directors (the "Board") has declared a one-time special dividend of US$1.00 per common share (the "Special Dividend") that shareholders of record as of the close of business on November 15, 2010 (the "Record Date") will be entitled to receive on December 22, 2010.

4 Nov 2010

Pharmaceuticals News and Research

Report: FDA conflict-of-interest rules too restrictive

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Sanofi Pasteur's dengue vaccine enters phase III trial in Australia

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Research Roundup: Basing insurance on results, not cost; Americans skeptical of public health efforts; seniors' comprehensive care

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

APP Drug Hotline to assist healthcare professionals with shortage issues

Al Jazeera examines international trade agreement negotiations, access to generic medicines in low-income countries

Ortho-McNeil terminates collaboration agreement with Arena on APD597 trial program

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Watson third quarter net revenue increases 33% to $882.4 million

Omeros third quarter net loss increases to $7.6 million

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

First Edition: November 4, 2010

Rockwell Medical third quarter sales increases 4.1% to $14.7 million

CaPre drug candidate effective in managing impaired glucose tolerance

Athersys secures three Therapeutic Discovery Project grants

Valeant declares one-time special dividend

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence